| Schedule of financial data for the one reportable segment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
June 30, |
|
June 30, |
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
|
Phase 2 study in WM |
|
$ |
495,000 |
|
$ |
2,791,000 |
|
$ |
1,128,000 |
|
$ |
4,985,000 |
Phase 1 study in pediatric tumors |
|
|
243,000 |
|
|
1,160,000 |
|
|
976,000 |
|
|
1,659,000 |
Manufacturing and related costs |
|
|
871,000 |
|
|
2,628,000 |
|
|
1,580,000 |
|
|
5,941,000 |
Pre-clinical projects cost |
|
|
145,000 |
|
|
31,000 |
|
|
652,000 |
|
|
52,000 |
General research and development costs |
|
|
636,000 |
|
|
735,000 |
|
|
1,481,000 |
|
|
1,797,000 |
General and administrative |
|
|
3,648,000 |
|
|
6,358,000 |
|
|
6,622,000 |
|
|
11,272,000 |
Other segment items |
|
|
(590,000) |
|
|
(12,784,000) |
|
|
(387,000) |
|
|
1,856,000 |
Segment and consolidated net loss |
|
$ |
5,448,000 |
|
$ |
919,000 |
|
$ |
12,052,000 |
|
$ |
27,562,000 |
|